Investor Relations

Stock Symbol JNJ
Current Price $98.75
Change $-0.45
Day High $99.71
Day Low $98.07
Volume 11,280,900
Trades 83,835
04/16/2014 4:00 PM
Minimum 20 mins delay.

Stock Transfer Agent
outside the U.S. and Canada

Investing in Johnson & Johnson.

Johnson & Johnson has been a part of people's lives for 128 years and a valuable part of their investments for approximately 70 years. Founded in 1886, we listed our shares on the New York Stock Exchange for public investors in 1944.

During our history, we have built the most comprehensive base of health care businesses in the world, generating approximately 70 percent of our revenues from No. 1 or No. 2 global leadership positions in our respective markets.

Our consistent performance has enabled us to deliver an exceptional track record of growth that few, if any, companies can claim: 30 consecutive years of adjusted earnings increases; and 51 consecutive years of dividend increases. Over the last 10 years, Johnson & Johnson stock generated a 8.9 percent total return for investors compared to a 7.4 percent total return for the S&P 500.(1)

E-Delivery of Annual Meeting and Proxy Materials

Johnson & Johnson is dedicated to improving the health and well-being of people everywhere. To fulfill this goal, we must protect the environments in which we work and live. A healthy planet and a healthy community go hand in hand. With this in mind, we now offer electronic versions of all of our company publications like the Annual Report.

Click here for the Johnson & Johnson 2013 Annual Report
Click here for the Johnson & Johnson 2014 Proxy Statement
Click here for the Johnson & Johnson 2013 Digital Annual Report

You can do your part as well. By reducing the amount of printed shareholder materials you receive, you can help protect the environment while quickly receiving important shareholder documents. In addition, reducing the printing and mailing costs associated with more traditional delivery methods allows us to control expenses in the interest of delivering more value for all our shareholders.

Registered Johnson & Johnson shareholders can sign up for electronic delivery of our reports and publications. Please go to or contact our transfer agent, Computershare, at 1-800-328-9033.

Beneficial (owned through a broker/bank) Johnson & Johnson shareholders can register for on-line delivery of materials by clicking here and following the easy directions to your account.

Investor News

April 15, 2014
Johnson & Johnson Reports 2014 First-Quarter Results:

April 12, 2014
Final Data from the Phase 2 COSMOS Study of Janssen's Once-Daily Simeprevir in Combination with Sofosbuvir Presented at The International Liver Congress 2014 of the European Association for the Study of the Liver (EASL)

April 8, 2014
Supplemental New Drug Application for IMBRUVICATM (ibrutinib) Submitted to the U.S. FDA

Investor Communications

April 24, 2014 at 10:00 AM ET
Johnson & Johnson 2014 Annual Meeting of Shareholders

April 15, 2014 at 8:30 AM ET
Johnson & Johnson First Quarter 2014 Earnings Call and Webcast

Financial Quick Links

Johnson & Johnson Reports 2014 First-Quarter Results

Sales of Key Products/Franchises Q1 2014

Reconciliation of Non-GAAP Financial Measures Q1 2014

5 Year Financial Review

1. Data source - Bloomberg